Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre,retrospective,chart review study

Abstract

Purpose

First, to assess drug utilization rates of capecitabine plus oxaliplatin (CAPOX) versus 5-fluorouracil plus oxaliplatin (mFOLFOX6) regimens in the treatment of stage IIB and stage III colon cancer. Second, to assess patient characteristics used to select CAPOX versus FOLFOX therapy, dose-limiting toxicities, dose intensities and treatment completion rates.

Methods

Patients with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6 were selected for the analysis. Protocol utilization rates, patient characteristics and toxicities of the two regimens were collected and compared by descriptive statistics.

Results

A total of 306 patients were included over study period. mFOLFOX6 is the most commonly used regimen with 69% utilization rate. CAPOX patients were younger (57 years old vs. 62 years old, p < 0.01), but no other significant differences were found. CAPOX was associated with more dose-limiting toxicities compared to mFOLFOX6 (95% vs. 82%, p < 0.01). Fewer patients completed the intended 24-week course of CAPOX compared to mFOLFOX6 (67% vs. 82%, p < 0.01).

Conclusion

FOLFOX is the most commonly utilized adjuvant treatment option for stage IIB and stage III colon cancer in British Columbia, and is associated with better tolerability and higher treatment completion rates.

Keywords

Colon cancer capecitabine fluorouracil oxaliplatin drug utilization

Get full access to this article

View all access options for this article.

References

Canadian Cancer Society. Colorectal cancer statistics – Canadian Cancer Society, www.cancer.ca/en/cancer-information/cancer-type/colorectal/statistics/?region=qc (accessed 6 May 2016).

Schmoll

Van Cutsem

Stein

et al.

ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–2516.

Colon Cancer Treatment (PDQ®). National Cancer Institute, www.cancer.gov/cancertopics/pdq/treatment/colon/Patient/page2 (accessed 26 July 2014).

Schmoll

H-J

Tabernero

Maroun

et al.

Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. JCO 2015; 33: 3733–3740.

André

Boni

Mounedji-Boudiaf

et al.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351.

Rothenberg

Cox

Butts

et al.

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19: 1720–1726.

Comella

Massidda

Filippelli

et al.

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 2009; 135: 217–226.

Ducreux

Bennouna

Hebbar

et al.

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011; 128: 682–690.

Cassidy

Clarke

Díaz-Rubio

et al.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006–2012.

10.

Porschen

Arkenau

H-T

Kubicka

et al.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group. J Clin Oncol 2007; 25: 4217–4223.

11.

Arkenau

H-T

Arnold

Cassidy

et al.

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910–5917.

12.

Pectasides D, Karavasilis V, Papaxoinis G, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer 2015; 15: 384.

13.

Ohta H, Hayashi T, Murai S, et al. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, http://link.springer.com/10.1007/s00280-017-3294-9 (2017, accessed 23 April 2017).

14.

GraphPad Software, www.graphpad.com/quickcalcs/ (accessed 1 May 2016).

15.

Chang

Ruan

et al.

Population-based cost-minimization analysis of CAPOX versus modified FOLFOX6 in the adjuvant treatment of stage III colon cancer. Clin Colorectal Canc 2016; 15: 158–163.

16.

Loree

Mulder

Ghosh

et al.

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Canc 2014; 13: 172–177.

17.

Kawakami

Nakamoto

Yokokawa

et al.

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence 2015; 9: 561–567.